Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main (gene editing) focus: Next-generation cell therapies
Company stage: Pre-clinical
Diseases: Solid tumours
Genome editing tool: CRISPR
Funding stage: Private
Location: Boston, MA, USA
Affini-T Therapeutics is focused on developing pioneering engineered T cell receptor (TCR) T cell therapies. The company's involvement in the gene-editing space comes through its partnership with Metagenomi, although lead programmes have yet to be announced as well as the specifics regarding the gene-editing system in use.